Cosmo Pharmaceuticals (OTC:CMOPF – Get Free Report)’s share price rose 0.3% on Friday . The stock traded as high as C$80.25 and last traded at C$80.25. Approximately 13 shares changed hands during trading, a decline of 96% from the average daily volume of 301 shares. The stock had previously closed at C$80.00.
Cosmo Pharmaceuticals Trading Up 0.3 %
The business’s fifty day moving average price is C$79.30 and its 200-day moving average price is C$71.68.
Cosmo Pharmaceuticals Company Profile
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy.
Featured Stories
- Five stocks we like better than Cosmo Pharmaceuticals
- What Investors Need to Know to Beat the Market
- McDonald’s Stock: Balancing Value and Innovation
- How to Use the MarketBeat Excel Dividend Calculator
- MarketBeat Week in Review – 6/17 – 6/21
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Sarepta Therapeutics Stock Soars on FDA Approval
Receive News & Ratings for Cosmo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cosmo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.